

Juehua Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579061/publications.pdf>

Version: 2024-02-01

50
papers

886
citations

516710

16
h-index

501196

28
g-index

51
all docs

51
docs citations

51
times ranked

1638
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. <i>Modern Pathology</i> , 2011, 24, 1433-1443.	5.5	96
2	Immunophenotypic Variations in Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 699-706.	0.7	82
3	Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. <i>Human Pathology</i> , 2018, 82, 140-148.	2.0	64
4	Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4898-4906.	7.0	61
5	GATA family transcriptional factors: emerging suspects in hematologic disorders. <i>Experimental Hematology and Oncology</i> , 2015, 4, 28.	5.0	57
6	CAAX-box protein, prenylation process and carcinogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 312-25.	0.0	55
7	Germline variants drive myelodysplastic syndrome in young adults. <i>Leukemia</i> , 2021, 35, 2439-2444.	7.2	43
8	Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. <i>Blood</i> , 2014, 124, 780-790.	1.4	42
9	EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. <i>Modern Pathology</i> , 2017, 30, 1100-1115.	5.5	30
10	Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2017, 128, 125-140.	8.2	30
11	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. <i>Leukemia and Lymphoma</i> , 2015, 56, 2895-2901.	1.3	28
12	Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. <i>International Journal of Hematology</i> , 2015, 102, 587-593.	1.6	27
13	Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. <i>Journal of Hematology and Oncology</i> , 2014, 7, 36.	17.0	25
14	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. <i>Blood Cancer Journal</i> , 2021, 11, 39.	6.2	22
15	Ineffective erythropoiesis caused by binucleated late-stage erythroblasts in mDia2 hematopoietic specific knockout mice. <i>Haematologica</i> , 2016, 101, e1-e5.	3.5	21
16	Flow Cytometric Analysis of Lymphoid Enhancer-Binding Factor 1 in Diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 143, 214-222.	0.7	18
17	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. <i>International Journal of Hematology</i> , 2017, 105, 44-51.	1.6	15
18	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. <i>Diagnostic Pathology</i> , 2018, 13, 78.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Bone marrow involvement by subcutaneous Panniculitis-like T-cell lymphoma: a report of three cases. <i>Modern Pathology</i> , 2014, 27, 800-807.	5.5	14
20	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, <i>CDKN2A</i> loss, and <i>TP53</i> mutations: A multi-institutional study. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 484-494.	2.8	14
21	Loss of <i>mDia1</i> causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium. <i>Blood Advances</i> , 2017, 1, 1650-1656.	5.2	10
22	High Frequency of MYD88 L265P Mutation in Primary Ocular Adnexal Marginal Zone Lymphoma and Its Clinicopathologic Correlation: A Study From a Single Institution. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 483-493.	2.5	10
23	Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. <i>Human Pathology</i> , 2020, 98, 22-31.	2.0	10
24	H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell function. <i>Scientific Reports</i> , 2016, 6, 19589.	3.3	9
25	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. <i>Leukemia</i> , 2021, 35, 2097-2101.	7.2	9
26	Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 688-688.	1.4	8
27	Rare myeloid sarcoma with <i>KMT2A</i> (<i>MLL</i>)- <i>ELL</i> fusion presenting as a vaginal wall mass. <i>Diagnostic Pathology</i> , 2019, 14, 26.	2.0	7
28	Myeloid Neoplasm With Germline Predisposition: A 2016 Update for Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 13-22.	2.5	7
29	An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. <i>Human Pathology</i> , 2019, 91, 1-10.	2.0	6
30	Comparison of myeloid neoplasms with nonclassic <i>3q26.2</i> <i>MECOM</i> versus classic <i>inv(3)</i> (<i>t(3;3)</i>) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of <i>MECOM</i> activation. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 71-80.	2.8	6
31	Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test. <i>Antibody Therapeutics</i> , 2022, 5, 55-62.	1.9	6
32	Flow cytometric detection of altered signaling in myelodysplastic syndrome and cytopenia. <i>Leukemia Research</i> , 2015, 39, 1396-1404.	0.8	5
33	Distinctive Flow Cytometric and Mutational Profile of Acute Myeloid Leukemia With <i>t(8;16)(p11;p13)</i> Translocation. <i>American Journal of Clinical Pathology</i> , 2022, 157, 701-708.	0.7	5
34	A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 284-291.	1.1	5
35	Distinctive Clinicopathologic Features of Monomorphic B-cell Post-transplant Lymphoproliferative Disorders in Children. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 318-326.	1.0	4
36	Molecular Pathogenesis in Myeloid Neoplasms with Germline Predisposition. <i>Life</i> , 2022, 12, 46.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis. <i>Human Pathology</i> , 2020, 105, 37-46.	2.0	3
38	Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication. <i>Blood</i> , 2019, 134, 475-475.	1.4	3
39	Refractory hemophagocytic lymphohistiocytosis in an adult patient with occult ALK-Positive anaplastic large cell lymphoma and a heterozygous MEFV mutation. <i>Leukemia and Lymphoma</i> , 2022, 63, 495-498.	1.3	3
40	Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of <i>TP53</i> mutation and genetic complexity. <i>Leukemia and Lymphoma</i> , 2021, 62, 3304-3307.	1.3	2
41	Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia. <i>Blood</i> , 2015, 126, 3477-3477.	1.4	2
42	Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation. <i>Blood</i> , 2019, 134, 3990-3990.	1.4	1
43	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
44	Concurrent CD5-negative small lymphocytic lymphoma (SLL) and CD5-positive metastatic carcinoma of unknown primary in a lymph node biopsy. <i>Journal of Hematopathology</i> , 2013, 6, 45-50.	0.4	0
45	Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive Natural killer-cell leukemia/lymphoma. <i>Human Pathology</i> , 2020, 105, 20-30.	2.0	0
46	Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 1557-1557.	1.4	0
47	Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients. <i>Blood</i> , 2013, 122, 4329-4329.	1.4	0
48	Prevalence, Type, and Risk Factors for Bleeding in a Large Cohort of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2014, 124, 3207-3207.	1.4	0
49	Clinical and Pathologic Features of Intravascular Large B Cell Lymphoma: A Single Institution Experience. <i>Blood</i> , 2015, 126, 5055-5055.	1.4	0
50	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0